P2RY13 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3361087	1.00	4/20
SCHEMBL7196936	1.00	4/20
SCHEMBL3361094	0.98	4/20
SCHEMBL3361090	0.87	4/20
SCHEMBL7093360	0.73	4/20
SCHEMBL7091376	0.71	4/20
SCHEMBL7091071	0.70	4/20
SCHEMBL5287746	0.69	4/20
SCHEMBL7196930	0.69	4/20
SCHEMBL7196945	0.69	4/20
SCHEMBL7090990	0.65	4/20
SCHEMBL7094651	0.65	4/20
SCHEMBL7093542	0.63	4/20
SCHEMBL7095169	0.62	4/20
SCHEMBL7093516	0.62	4/20
SCHEMBL7094321	0.62	4/20
SCHEMBL7093079	0.61	4/20
SCHEMBL7091095	0.61	4/20
SCHEMBL7094324	0.61	4/20
SCHEMBL7096181	0.61	4/20

Clinical trials — most relevant to P2RY13 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease	PHASE4	COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI	PHASE4	UNKNOWN
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine	PHASE4	COMPLETED
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease	PHASE4	COMPLETED
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR	PHASE4	NOT_YET_RECRUITING
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects	PHASE4	COMPLETED
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study	PHASE4	COMPLETED
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
Clopidogrel for the Prevention of Exacerbations in Severe COPD	PHASE3	UNKNOWN
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention	PHASE2	UNKNOWN
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects	PHASE1	COMPLETED
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese	PHASE1	COMPLETED
A Genomic Approach for Clopidogrel in Caribbean Hispanics	EARLY_PHASE1	COMPLETED
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)	nan	ACTIVE_NOT_RECRUITING
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention	nan	COMPLETED
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Platelet Function in Resuscitated Patients	nan	COMPLETED
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome	nan	COMPLETED
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders	nan	UNKNOWN
Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia	nan	RECRUITING
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES	nan	UNKNOWN
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RY13 binder may also engage these)

Protein	Name	Similarity
Q6GUG4	—	1.000	Q6GUG4 →
Q9D8I2	—	0.997	Q9D8I2 →
Q9BE53	—	0.982	Q9BE53 →
P2RY12	P2Y purinoceptor 12	0.954	landscape →
P2RY14	P2Y purinoceptor 14	0.953	landscape →
Q3SX17	—	0.952	Q3SX17 →
O35881	—	0.951	O35881 →
Q95KC3	—	0.951	Q95KC3 →
Q9CPV9	—	0.948	Q9CPV9 →
Q9EPX4	—	0.948	Q9EPX4 →
Q9ESG6	—	0.947	Q9ESG6 →
P55086	—	0.940	P55086 →
Q98907	—	0.936	Q98907 →
O93361	—	0.933	O93361 →
Q2HJA4	—	0.932	Q2HJA4 →
F2RL1	Proteinase-activated receptor 2	0.932	landscape →
Q63645	—	0.931	Q63645 →
LPAR4	Lysophosphatidic acid receptor 4	0.929	landscape →
Q8BLG2	—	0.929	Q8BLG2 →
P32250	—	0.927	P32250 →
Q4G072	—	0.924	Q4G072 →
P33534	—	0.923	P33534 →
GRPR	Gastrin-releasing peptide receptor	0.922	landscape →
P34975	—	0.921	P34975 →
LPAR6	Lysophosphatidic acid receptor 6	0.920	landscape →
B3G515	—	0.920	B3G515 →
F7EQ49	—	0.919	F7EQ49 →
P42866	—	0.919	P42866 →
P21729	—	0.918	P21729 →
GPER1	G-protein coupled estrogen receptor 1	0.918	landscape →